Companies / BMY vs ZTS
BMY vs ZTS: Bristol Myers Squibb and Zoetis
Bristol Myers Squibb (BMY) reported $48.2B in revenue against a 14.6% net margin, while Zoetis (ZTS) reported $9.5B at a 28.2% net margin, most recently.
| Metric | BMY | ZTS |
|---|---|---|
| Revenue | $48.2B | $9.5B |
| Net Income | $7.1B | $2.7B |
| Gross Margin | 71.1% | 71.8% |
| Operating Margin | 19.4% | — |
| EPS (Diluted) | $3.46 | $6.02 |
| Free Cash Flow | $12.8B | $2.3B |
| Total Debt | $47.1B | $9.0B |
| P/E Ratio | 15.6× | 20.9× |
| P/B Ratio | n/m | 16.1× |
| Stock Price | $63.16 | $82.13 |
Free: last 5 years
| Fiscal year | FY2011 🔒 | FY2012 🔒 | FY2013 🔒 | FY2014 🔒 | FY2015 🔒 | FY2016 🔒 | FY2017 🔒 | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMY Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $46.4B | $46.2B | $45.0B | $48.3B | $48.2B |
| ZTS Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $7.8B | $8.1B | $8.5B | $9.3B | $9.5B |